Alexander Mclean Marshall
University of Bristol(GB)
Publications by Year
Research Areas
Particle physics theoretical and experimental studies, Quantum Chromodynamics and Particle Interactions, High-Energy Particle Collisions Research, Neutrino Physics Research, Multiple Myeloma Research and Treatments
Most-Cited Works
- → Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration(2024)14 cited
- → Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration(2023)10 cited
- → Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma(2023)10 cited
- → Effective stakeholder engagement for decision-relevant research on food-energy-water systems(2025)5 cited
- → P-265: Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: analysis of the Optum electronic health records and commercial claims database(2022)3 cited
- → P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA(2023)1 cited
- → P-237: Real-world treatment patterns and clinical outcomes in patients with triple-class exposed relapsed or refractory multiple myeloma in United States clinical practice(2022)1 cited
- → P-294 Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma(2023)
- → OAB-054: Comparative efficacy of teclistamab versus real-world physician’s choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma(2022)
- → P-281: Adjusted comparison of teclistamab versus physician’s choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma(2022)